Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab.

导出 OA

翻译打印收藏纠错

作者： Shujie,Liu ^[1] ; Shuai,Yan ^[1] ; Jie,Zhu ^[1] ; Ruiqing,Lu ^[1] ; Chujie,Kang ^[2] ; Kang,Tang ^[2] ; Jinfeng,Zeng ^[2] ; Mingmei,Ding ^[1] ; Zixiang,Guo ^[1] ; Xianxin,Lai ^[1] ; Yinan,Jiang ^[1] ; Siqing,Wu ^[1] ; Lihua,Zhou ^[1] ; Litao,Sun ^[2] ; Zhong-Wei,Zhou ^[1]

作者单位： School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China. ^[1] School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China. ^[2]

关键词 FTH1 cetuximab resistance ferroptosis head and neck squamous cell carcinomas

主题词抗体, 单克隆(Antibodies, Monoclonal);癌, 鳞状细胞(Carcinoma, Squamous Cell);细胞系, 肿瘤(Cell Line, Tumor);头颈部肿瘤(Head and Neck Neoplasms);人类(Humans);舌肿瘤(Tongue Neoplasms)

DOI 10.3390/ijms23169014

PMID 36012290

发布时间 2022-08-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交